Elisabetta Magrini
Azienda USL di Bologna · 69 works · 3,727 citations · h-index 20
Top works
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
- Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer
- Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC
- Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial
- CD38: A multi-lineage cell activation molecule with a split personality
- Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
- HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
- Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib
- EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
- Clinical experience with gefitinib: An update
- In vitro testing of the potential for orthopedic bone cements to cause apoptosis of osteoblast-like cells
- Mucoepidermoid carcinoma of the breast
- Malignant granular cell tumor of the lateral femoral cutaneous nerve: Report of a case with cytogenetic analysis
- Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC)
- Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20
- Acquisition of i(8q) as an early event in malignant triton tumors
- Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma
- High proliferative activity and chromosomal instability in oral lichen planus
- Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma
- EGFR, HER2, and phospho-Akt are not predictive factors for response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)